YARROW BIOSCIENCE, INC. Income (Loss) Attributable to Parent, before Tax
YARROW BIOSCIENCE, INC. (YARW) reported Income (Loss) Attributable to Parent, before Tax of -$26.48 million for the 12-month period ending 2025-12-31, per its S-4/A filed 2026-06-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossAttributableToParent · last filed 2026-06-03
- YARROW BIOSCIENCE, INC. income (loss) attributable to parent, before tax for fiscal 2023 was -$28.45M.
- YARROW BIOSCIENCE, INC. income (loss) attributable to parent, before tax for fiscal 2022 was -$23.19M, a 131.44% decline from fiscal 2021.
- YARROW BIOSCIENCE, INC. income (loss) attributable to parent, before tax for fiscal 2021 was $73.78M.
| Period end | Income (Loss) Attributable to Parent, before Tax 12 month | Income (Loss) Attributable to Parent, before Tax 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$26.48M S-4/A · filed 2026-06-03 | |
| 2024-12-31 | -$39.83M S-4/A · filed 2026-06-03 | |
| 2023-12-31 | -$28.45M 10-K · filed 2025-03-06 | |
| 2022-12-31 | -$23.19M 10-K · filed 2024-03-01 | $23.19M 10-K · filed 2023-03-14 |
| 2021-12-31 | $73.78M 10-K · filed 2023-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B |